Dovato is a complete, one-pill, once-daily HIV-1 treatment regimen [1]. It combines dolutegravir, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) [1]. This combination targets the HIV virus in two different ways [1].
How does Dovato work to treat HIV?
Dovato functions by preventing HIV from multiplying in the body [1]. Dolutegravir inhibits an enzyme called integrase, which HIV needs to insert its genetic material into human cells. Lamivudine works by being incorporated into the growing DNA chain of HIV, causing the chain to terminate and preventing the virus from making copies of itself [1].
What is the recommended dosage for Dovato?
The standard recommended dose for Dovato is one tablet taken once daily [1]. It is important to take Dovato at the same time each day, with or without food [1].
What are the common side effects of Dovato?
Common side effects reported by individuals taking Dovato include headache, diarrhea, nausea, insomnia, and fatigue [1]. Most side effects are mild to moderate [1].
Are there any serious risks associated with Dovato?
Serious risks associated with Dovato can include hypersensitivity reactions, liver problems, and lactic acidosis [1]. Patients should seek immediate medical attention if they experience symptoms like severe rash, fever, severe fatigue, dark urine, or yellowing of the skin or eyes [1].
How does Dovato compare to other HIV treatment options?
Dovato offers a single-tablet, dual-therapy regimen, which can be an advantage for some patients by reducing pill burden compared to multi-drug regimens [1]. It is an option for individuals with no history of HIV-1 aldehyde dehydrogenase 2 (ALDH2) deficiency or known resistance to its components [1].
When does the patent for Dovato expire?
Information regarding specific patent expiry dates for Dovato would typically be found on specialized drug patent tracking websites. DrugPatentWatch.com provides resources for patent information [2].
Can generic versions of Dovato be developed?
The development of generic versions of Dovato, also known as biosimilars for biologics or generics for small molecules, is contingent on patent expiry and regulatory approval [2]. Once patents expire, companies can seek approval to market generic alternatives, which often leads to lower prices.
Who manufactures Dovato?
Dovato is manufactured by ViiV Healthcare [1]. ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, with Shionogi also as a partner [1].
Where can I find more information on Dovato?
More detailed information on Dovato, including prescribing information, clinical studies, and patient resources, can be found through ViiV Healthcare and the U.S. Food and Drug Administration (FDA) [1].
What clinical data supports Dovato's effectiveness?
Dovato's efficacy and safety have been demonstrated in clinical trials, such as the global Phase III GEMINI-1 and GEMINI-2 studies [1]. These studies showed that Dovato maintained viral suppression in adults with HIV-1 who were switching from established multi-drug regimens [1].
---
Sources:
[1] ViiV Healthcare. (n.d.). Dovato Prescribing Information. https://www.viivhealthcare.com/our-medicines/dovato/
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/